Stock Scorecard

Stock Summary for Mesoblast Ltd (MESO) - $18.75 as of 10/8/2025 4:20:19 PM EST

Total Score

5 out of 30

Safety Score

31 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MESO

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MESO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MESO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MESO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MESO (31 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for MESO

Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday - Century Aluminum ( NASDAQ:CENX ) , Absci ( NASDAQ:ABSI ) 10/8/2025 2:39:00 PM
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch 10/6/2025 11:24:00 PM
Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Arteris ( NASDAQ:AIP ) , Advanced Micro Devices ( NASDAQ:AMD ) 10/6/2025 1:01:00 PM
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Rich Sparkle Holdings ( NASDAQ:ANPA ) , International Paper ( NYSE:IP ) 10/6/2025 12:09:00 PM
Mesoblast Shares Are Rising Higher: What's Behind The Move? - Mesoblast ( NASDAQ:MESO ) 10/3/2025 7:50:00 PM
White Mountains Insurance, Rumble, Mesoblast And Other Big Stocks Moving Higher On Friday - Diginex ( NASDAQ:DGNX ) , Cipher Mining ( NASDAQ:CIFR ) 10/3/2025 2:36:00 PM
Ryoncil® Receives J-Code From Medicare & Medicaid Services ( CMS ) Facilitating Reimbursement and Broader Patient Access - Mesoblast ( NASDAQ:MESO ) 10/3/2025 1:04:00 AM
Ryoncil® Receives J-Code From Medicare & Medicaid Services ( CMS ) Facilitating Reimbursement and Broader Patient Access 10/3/2025 1:04:00 AM
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs - Mesoblast ( NASDAQ:MESO ) 9/26/2025 5:49:00 AM
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs 9/26/2025 5:49:00 AM

Financial Details for MESO

Company Overview
Ticker MESO
Company Name Mesoblast Ltd
Country USA
Description Mesoblast Ltd is a leading biopharmaceutical company headquartered in Melbourne, Australia, specializing in the development and commercialization of innovative allogeneic cellular therapies. With a focus on addressing unmet medical needs, Mesoblast harnesses proprietary technologies to create transformative treatments for a range of conditions, including spine disorders, cardiovascular diseases, and inflammatory diseases. The company's advanced product pipeline, bolstered by robust clinical data, aims to provide patients with effective and long-lasting solutions, positioning Mesoblast as a key player in the regenerative medicine space.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2024
Next Earnings Date 11/26/2025

Stock Price History
Last Day Price 18.75
Price 4 Years Ago 9.60
Last Day Price Updated 10/8/2025 4:20:19 PM EST
Last Day Volume 370,886
Average Daily Volume 279,604
52-Week High 22.00
52-Week Low 7.09
Last Price to 52 Week Low 164.46%

Valuation Measures
Trailing PE N/A
Industry PE 22.22
Sector PE 41.70
5-Year Average PE -20.52
Free Cash Flow Ratio 14.88
Industry Free Cash Flow Ratio 14.45
Sector Free Cash Flow Ratio 30.25
Current Ratio Most Recent Quarter 1.99
Total Cash Per Share 1.26
Book Value Per Share Most Recent Quarter 0.47
Price to Book Ratio 3.65
Industry Price to Book Ratio 29.58
Sector Price to Book Ratio 32.02
Price to Sales Ratio Twelve Trailing Months 137.15
Industry Price to Sales Ratio Twelve Trailing Months 44.16
Sector Price to Sales Ratio Twelve Trailing Months 20.22
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 2

Share Statistics
Total Shares Outstanding 128,117,000
Market Capitalization 2,402,193,750
Institutional Ownership 2.68%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -16.13%
Reported EPS 12 Trailing Months -0.85
Reported EPS Past Year 0.00
Reported EPS Prior Year -0.36
Net Income Twelve Trailing Months -103,351,000
Net Income Past Year -102,142,000
Net Income Prior Year -87,956,000
Quarterly Revenue Growth YOY 458.60%
5-Year Revenue Growth -11.76%
Operating Margin Twelve Trailing Months -302.40%

Balance Sheet
Total Cash Most Recent Quarter 161,158,000
Total Cash Past Year 161,158,000
Total Cash Prior Year 62,563,000
Net Cash Position Most Recent Quarter 93,419,000
Net Cash Position Past Year 93,419,000
Long Term Debt Past Year 67,739,000
Long Term Debt Prior Year 100,483,000
Total Debt Most Recent Quarter 67,739,000
Equity to Debt Ratio Past Year 0.90
Equity to Debt Ratio Most Recent Quarter 0.90
Total Stockholder Equity Past Year 597,442,000
Total Stockholder Equity Prior Year 480,355,000
Total Stockholder Equity Most Recent Quarter 597,442,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -33,868,500
Free Cash Flow Per Share Twelve Trailing Months -0.26
Free Cash Flow Past Year -50,684,000
Free Cash Flow Prior Year -48,789,000

Options
Put/Call Ratio 0.03
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.58
MACD Signal 0.41
20-Day Bollinger Lower Band 9.16
20-Day Bollinger Middle Band 14.16
20-Day Bollinger Upper Band 19.16
Beta 1.17
RSI 62.61
50-Day SMA 13.66
150-Day SMA 8.22
200-Day SMA 7.96

System
Modified 10/7/2025 4:22:12 AM EST